References
- Evans A, Gilbert E, Zandstra R. The increasing incidence of central nervous system leukemia in children. Cancer 1970; 26: 404–409
- Price R A, Jamieson P. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 1975; 35: 306–318
- Pizzo P A, Poplack D G, Bleyer W A. Neurotoxicities of current leukemia therapy. Am J Pediatr Oncol 1979; 1: 127–140
- Feizer C F. Adverse effects on intrathecal methotrexate in children with acute leukemia in remission. Blood 1975; 45: 189–195
- Oliff A W, Bleyer A, Poplack D G. Acute encephalopathy after initiation of cranial irradiation for meningeal leukemia. Lancet 1978; ii: 13–15
- Whittaker J A. Coma associated with vincristine therapy. Br Med J 1973; iv: 335–337
- Johnson F L. Seizures associated with vincristine sulphate therapy. J Pediatr 1973; 82: 699–702
- O'Sullivan M J, Ekert H. Vincristine toxicity unrelated to dose. Arch Dis Child 1976; 51: 289–292
- Oettgen H F. Toxicity of E. coli. Asparaginase in man. Cancer 1970; 25: 253–278
- Cairo M S. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol 1982; 4: 335–339
- Haskell C M. L-asparaginase: Therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969; 281: 1028–1034
- Land V G. Toxicity of L-asparaginase in children with advanced leukemia. Cancer 1972; 30: 339–347
- Priest JR. A syndrome of thrombosis complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100: 984–989
- Cairo M S. Intrathecal hemorrhage and focal seizures secondary to the use of L-asparaginase during induction therapy of acute lymphoblastic leukemia. J Pediatr 1980; 97: 829–833
- Vellanga E. The influence of L-asparaginase therapy on the fibrinolytic system. Br J Haematol 1984; 57: 247–254
- Weiss H D, Walker M D, Weirnik P H. Neurotoxicity of commonly used antineoplastic agents (Part I). N Engl J Med 1974; 268: 75–81
- Moure J MB, Whittacker J P, Bodey G P. Electroencephalogram changes secondary to asparaginase. ARch Neurol 1970; 23: 365–368